Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + capecitabine + endostar
- Development stage
- Unknown
- Lead developer
- Shanghai Jiao Tong University School of Medicine
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
OXCE is a combination therapeutic regimen comprising the chemotherapy drugs oxaliplatin and capecitabine (collectively known as XELOX or CapeOx) and the anti-angiogenic agent Endostar (recombinant human endostatin). Developed for the treatment of advanced colorectal cancer, this regimen combines cytotoxic DNA-damaging effects with the inhibition of tumor vascularization. Oxaliplatin is a platinum-based agent that forms DNA adducts, while capecitabine is an oral prodrug of 5-fluorouracil that inhibits thymidylate synthase. Endostar, a modified recombinant human endostatin expressed in *E. coli*, inhibits the proliferation and migration of vascular endothelial cells by antagonizing VEGF-mediated signaling. This combination is primarily investigated by the Shanghai Jiao Tong University School of Medicine as a first-line therapy to improve survival outcomes in patients with metastatic or advanced colorectal malignancies.
- Other names
- XELOX + EndostarCapeOx + EndostarEndostar + XELOX
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on oxaliplatin + capecitabine + endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + capecitabine + endostar.